{"id":"https://genegraph.clinicalgenome.org/r/e2267ada-584b-4368-a73a-90174d74f1d3v2.0","type":"EvidenceStrengthAssertion","dc:description":"The relationship between FAR1 and FAR1 Upregulation, a newly described autosomal dominant disorder, was evaluated using the ClinGen Clinical Validity Framework as of August, 2021. FAR1 encodes a peroxisomal membrane protein that is required for the reduction of fatty acids to fatty alcohols. The disorder is characterized by spastic paraparesis and bilateral congenital/juvenile cataracts, in most combined with speech and gross motor developmental delay and truncal hypotonia (PMID: 33239752). The clinical phenotypes seen in affected individuals overlap with those of the autosomal recessive condition, FAR1 deficiency, caused by biallelic variants in FAR1. However, the biochemical phenotypes are in contrast - while FAR1 deficiency is associated with plasmalogen deficiency, FAR1 upregulation is characterized by elevated plasmalogen levels. FAR1 protein levels are subject to plasmalogen-dependent feedback regulation (PMID: 33239752). FAR1 was first reported in relation to autosomal dominant FAR1 Upregulation in 2020 (Ferdinandusseet al, 2020; PMID: 33239752), and so far this is the only report. Variants in this gene that cause FAR1 upregulation (n = 3) all affect the same residue (Arg480) and arise de novo. Evidence supporting this gene-disease relationship includes case-level data and experimental data. \n   \nSummary of Case Level Data (9.2 points):\nEighteen unrelated patients from around the world  in 1 publication (PMID: 33239752, 37335441, 39074165, 36781603) have been reported with de novo heterozygous variants in FAR1. Of note, all variants reported involve the same codon - Arg480.\n\nThe mechanism is reported to be gain of function (PMID: 33239752). \n  \nSummary of experimental data (1 point):\nFAR1 has a functional role in plasmalogen synthesis as outlined in PMIDs: 15220348 and 24108123.  \n  \nIn summary, the evidence to support the gene-disease relationship of FAR1 and FAR1 upregulation is moderate. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged. This gene-disease pair was originally evaluated by the Peroxisomal GCEP on January 12, 2023. It was reevaluated on June 6, 2025 (SOP v 10). Although additional cases were published (PMIDs: 37335441, 39074165, 36781603), the classification did not change. \n\nLumping and Splitting Considerations: \nOMIM entities: Cataracts, spastic paraparesis, and speech delay\t(MIM# 619338), Peroxisomal fatty acyl-CoA reductase 1 disorder\t(MIM# 616154). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found differences in the molecular mechanisms, inheritance patterns AND phenotypic presentation. Therefore, we have split curations for the disease entities, FAR1 deficiency and FAR1 upregulation (terms introduced by the peroxisomal GCEP).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/e2267ada-584b-4368-a73a-90174d74f1d3","GCISnapshot":"https://genegraph.clinicalgenome.org/r/1068b8e8-36a1-4110-9ab4-45f9d4ece894","calculatedEvidenceStrength":"Moderate","changes":[{"id":"cg:newEvidence"},{"id":"cg:summaryChange"},{"id":"cg:sopChange"},{"id":"cg:otherTextChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/1068b8e8-36a1-4110-9ab4-45f9d4ece894_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10049","date":"2025-07-08T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/1068b8e8-36a1-4110-9ab4-45f9d4ece894_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10049","date":"2025-07-25T04:19:11.960Z","role":"Publisher"}],"curationReasons":["RecurationTiming"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1068b8e8-36a1-4110-9ab4-45f9d4ece894_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0b257c3c-f710-4e09-aad2-24653c9a916d","type":"EvidenceLine","dc:description":"The proband was heterozygous for the Arg480Cys missense variant. No functional analysis is available. The variant is scored 0.5 points for a rare de novo missense variant with confirmation of maternity and paternity. Note, FAR1 is constrained for missene variation (gnomAD Z score: 3.3). Score may be upgraded upon expert review.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0b257c3c-f710-4e09-aad2-24653c9a916d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33239752","allele":{"id":"https://genegraph.clinicalgenome.org/r/dccf7be1-e8aa-4024-8527-1a53ca1ee471","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032228.6(FAR1):c.1438C>T (p.Arg480Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16619294"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0564fbfe-2d64-45cf-91cc-8c7b17ed7e7f","type":"EvidenceLine","dc:description":"Score increased based on confirmed de novo status and confirmed maternity and paternity by trio exome analysis","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0564fbfe-2d64-45cf-91cc-8c7b17ed7e7f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36781603","allele":{"id":"https://genegraph.clinicalgenome.org/r/dccf7be1-e8aa-4024-8527-1a53ca1ee471"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/dee52fb1-56c8-426c-8c7c-e1c04b4564f8","type":"EvidenceLine","dc:description":"The proband was heterozygous for the Arg480Cys missense variant. No functional analysis is available. The variant is scored 0.5 points for a rare de novo missense variant with confirmation of maternity and paternity. Note, FAR1 is constrained for missene variation (gnomAD Z score: 3.3). Score may be upgraded upon expert review.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dee52fb1-56c8-426c-8c7c-e1c04b4564f8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33239752","allele":{"id":"https://genegraph.clinicalgenome.org/r/dccf7be1-e8aa-4024-8527-1a53ca1ee471"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f6a429c7-4bc7-4e87-af9d-c7f744877405","type":"EvidenceLine","dc:description":"The proband was heterozygous for the Arg480Cys missense variant. No functional analysis is available. The variant is scored 0.5 points for a rare de novo missense variant with confirmation of maternity and paternity. Note, FAR1 is constrained for missene variation (gnomAD Z score: 3.3). Score may be upgraded upon expert review.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f6a429c7-4bc7-4e87-af9d-c7f744877405_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33239752","allele":{"id":"https://genegraph.clinicalgenome.org/r/dccf7be1-e8aa-4024-8527-1a53ca1ee471"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/cd7cfc0e-dd68-40ca-8534-d49e6a84fab7","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cd7cfc0e-dd68-40ca-8534-d49e6a84fab7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36781603","allele":{"id":"https://genegraph.clinicalgenome.org/r/dccf7be1-e8aa-4024-8527-1a53ca1ee471"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/e2d49275-2b0c-4a0e-829e-b4b388a03d08","type":"EvidenceLine","dc:description":"The proband was heterozygous for the Arg480His missense variant. Functional analysis in patient fibroblasts showed that enzyme activity of FAR1 was 379 pmol/h.mg protein compared to that in control subjects. FAR1 feedback regulation was impaired in patient cells - plasmalogen levels were increased by HDG treatment in control and patient cells. While FAR1 protein levels were decreased 31-47% in control cells, no consistent decrease of FAR1 levels were observed in the patient cells. Ether lipid synthesis was 4-fold higher in patient cells than control cells. Significant accumulation different ether lipid species was also noted in patient cells. The variant is scored 0.5 points for a rare de novo missense variant with confirmation of maternity and paternity. Functional analysis is on patient fibroblasts and is therefore not considered for score upgrade. Note, FAR1 is constrained for missene variation (gnomAD Z score: 3.3). Score may be upgraded upon expert review.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e2d49275-2b0c-4a0e-829e-b4b388a03d08_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33239752","allele":{"id":"https://genegraph.clinicalgenome.org/r/d7ed86cf-6980-40ad-8e09-d911d2f76eb1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032228.6(FAR1):c.1439G>A (p.Arg480His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16042832"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ece40705-7875-4744-91b0-1b62a857fe20","type":"EvidenceLine","dc:description":"The proband was heterozygous for the Arg480Cys missense variant. No functional analysis is available. The variant is scored 0.5 points for a rare de novo missense variant with confirmation of maternity and paternity. Note, FAR1 is constrained for missene variation (gnomAD Z score: 3.3). Score may be upgraded upon expert review.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ece40705-7875-4744-91b0-1b62a857fe20_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33239752","allele":{"id":"https://genegraph.clinicalgenome.org/r/dccf7be1-e8aa-4024-8527-1a53ca1ee471"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f140aa83-8831-42b0-9690-a0c4560b64fe","type":"EvidenceLine","dc:description":"The de novo missense variant is scored conservatively in the absence of functional evidence.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f140aa83-8831-42b0-9690-a0c4560b64fe_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37335441","allele":{"id":"https://genegraph.clinicalgenome.org/r/8eb349bd-9816-4ea3-bcb1-145915d009ed","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032228.6(FAR1):c.1438C>A (p.Arg480Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA379859372"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/f140aa83-8831-42b0-9690-a0c4560b64fe_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"While no direct functional evidence exists for this variant, other changes at this same residue have been reported in relation to FAR1 upregulation","functionalDataSupport":"No"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/51de217b-2b8d-4825-b9e0-f2d06c426892","type":"EvidenceLine","dc:description":"The proband was heterozygous for the Arg480Cys missense variant. No functional analysis is available. The variant is scored 0.5 points for a rare de novo missense variant with confirmation of maternity and paternity. Note, FAR1 is constrained for missene variation (gnomAD Z score: 3.3). Score may be upgraded upon expert review.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/51de217b-2b8d-4825-b9e0-f2d06c426892_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33239752","allele":{"id":"https://genegraph.clinicalgenome.org/r/dccf7be1-e8aa-4024-8527-1a53ca1ee471"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e2967e06-ede9-434f-89ad-681390f3e024","type":"EvidenceLine","dc:description":"The proband was heterozygous for the Arg480Leu missense variant. No functional analysis is available. The variant is scored 0.5 points for a rare de novo missense variant with confirmation of maternity and paternity. Note, FAR1 is constrained for missene variation (gnomAD Z score: 3.3). Score may be upgraded upon expert review.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e2967e06-ede9-434f-89ad-681390f3e024_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33239752","allele":{"id":"https://genegraph.clinicalgenome.org/r/273451e5-6835-44cf-9d31-00029f0c6dd1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032228.6(FAR1):c.1439G>T (p.Arg480Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA379859374"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/26e3ca2b-9915-4e58-829d-240f8a486fbf","type":"EvidenceLine","dc:description":" The proband was heterozygous for the Arg480His missense variant. No functional analysis is available. The variant is scored 0.5 points for a rare de novo missense variant with confirmation of maternity and paternity. Note, FAR1 is constrained for missense variation (gnomAD Z score: 3.3). Score may be upgraded upon expert review.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/26e3ca2b-9915-4e58-829d-240f8a486fbf_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33239752","allele":{"id":"https://genegraph.clinicalgenome.org/r/d7ed86cf-6980-40ad-8e09-d911d2f76eb1"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/cf7e7cf1-97d5-4619-9f5d-a6d2c78c2fc2","type":"EvidenceLine","dc:description":"The proband was heterozygous for the Arg480Cys missense variant. Functional analysis in patient fibroblasts showed that enzyme activity of FAR1 was 310 pmol/h.mg protein compared to that in control subjects. FAR1 feedback regulation was impaired in patient cells - plasmalogen levels were increased by HDG treatment in control and patient cells. While FAR1 protein levels were decreased 31-47% in control cells, no consistent decrease of FAR1 levels were observed in the patient cells. Ether lipid synthesis was 4-fold higher in patient cells than control cells. Significant accumulation different ether lipid species was also noted in patient cells. The variant is scored 0.5 points for a rare de novo missense variant with confirmation of maternity and paternity. Note, FAR1 is constrained for missene variation (gnomAD Z score: 3.3). Score may be upgraded upon expert review.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cf7e7cf1-97d5-4619-9f5d-a6d2c78c2fc2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33239752","allele":{"id":"https://genegraph.clinicalgenome.org/r/dccf7be1-e8aa-4024-8527-1a53ca1ee471"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/943fdd59-a655-405d-9a56-9f89ffc4a07a","type":"EvidenceLine","dc:description":"The proband was heterozygous for the Arg480His missense variant. No functional analysis is available. The variant is scored 0.5 points for a rare de novo missense variant with confirmation of maternity and paternity. Note, FAR1 is constrained for missene variation (gnomAD Z score: 3.3). Score may be upgraded upon expert review.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/943fdd59-a655-405d-9a56-9f89ffc4a07a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33239752","allele":{"id":"https://genegraph.clinicalgenome.org/r/d7ed86cf-6980-40ad-8e09-d911d2f76eb1"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/bf07f2c5-517a-47df-a8dd-5d0946907b18","type":"EvidenceLine","dc:description":" The proband was heterozygous for the Arg480Cys missense variant. No functional analysis is available. The variant is scored 0.5 points for a rare de novo missense variant with confirmation of maternity and paternity. Note, FAR1 is constrained for missene variation (gnomAD Z score: 3.3). Score may be upgraded upon expert review.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bf07f2c5-517a-47df-a8dd-5d0946907b18_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33239752","allele":{"id":"https://genegraph.clinicalgenome.org/r/dccf7be1-e8aa-4024-8527-1a53ca1ee471"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/782e2394-d486-4b2b-8843-704fbb76fd0a","type":"EvidenceLine","dc:description":"The proband was heterozygous for the Arg480His missense variant. Functional analysis in patient fibroblasts showed that enzyme activity of FAR1 was 379 pmol/h.mg protein compared to that in control subjects. FAR1 feedback regulation was impaired in patient cells - plasmalogen levels were increased by HDG treatment in control and patient cells. While FAR1 protein levels were decreased 31-47% in control cells, no consistent decrease of FAR1 levels were observed in the patient cells. Ether lipid synthesis was 4-fold higher in patient cells than control cells. Significant accumulation different ether lipid species was also noted in patient cells. The variant is scored 0.5 points for a rare de novo missense variant with confirmation of maternity and paternity. Note, FAR1 is constrained for missene variation (gnomAD Z score: 3.3). Score may be upgraded upon expert review.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/782e2394-d486-4b2b-8843-704fbb76fd0a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33239752","allele":{"id":"https://genegraph.clinicalgenome.org/r/d7ed86cf-6980-40ad-8e09-d911d2f76eb1"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9c49b43e-efaa-4bc0-b194-f919a7483c48","type":"EvidenceLine","dc:description":"In the absence of in-vitro functional evidence and de novo confirmation, the variant is scored minimal points.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9c49b43e-efaa-4bc0-b194-f919a7483c48_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36781603","allele":{"id":"https://genegraph.clinicalgenome.org/r/d7ed86cf-6980-40ad-8e09-d911d2f76eb1"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/a805662b-dc40-4121-b438-26d58b0974e0","type":"EvidenceLine","dc:description":"Score increased based on confirmed de novo status and confirmed maternity and paternity by trio exome analysis","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a805662b-dc40-4121-b438-26d58b0974e0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36781603","allele":{"id":"https://genegraph.clinicalgenome.org/r/dccf7be1-e8aa-4024-8527-1a53ca1ee471"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/0f1531ac-675e-4e16-a5e4-62df97972617","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0f1531ac-675e-4e16-a5e4-62df97972617_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/39074165","allele":{"id":"https://genegraph.clinicalgenome.org/r/dccf7be1-e8aa-4024-8527-1a53ca1ee471"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":9.2},{"id":"https://genegraph.clinicalgenome.org/r/1068b8e8-36a1-4110-9ab4-45f9d4ece894_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1068b8e8-36a1-4110-9ab4-45f9d4ece894_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fd8401be-c4a3-4bed-9302-5e20b0a3b8e5","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c8676a6d-8024-4534-92a4-448280aef124","type":"Finding","dc:description":"Patients show elevated levels of plasmalogens. Defects in plasmalogen synthesis leading to low levels of plasmalogens and to symptoms of FAR1 deficiency or RCDP 4. FAR1 dysregulation due to gain of function variants lead to elevated levels of plasmalogens. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15220348","rdfs:label":"Wang_Function","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1068b8e8-36a1-4110-9ab4-45f9d4ece894_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/02d5e538-75b8-498d-a703-3e157e6a27bf","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b6e87c18-8ecb-4b01-a9b3-605046b52201","type":"FunctionalAlteration","dc:description":"CHO-K1 Cell line stably expressing FLAG-Far1, cells were labeled with [14C]palmitate to assess plasmalogen synthesis. Plasmalogen synthesis was significantly higher in cells expressing Far1 (Figure 6). The authors also found that the stability of Far1 is regulated in response to the level of plasmalogens in the CHO-K1 cells; Degradation of Far1 is inhibited in plasmalogen‚Äêdeficient cells, whereas elevation of cellular PlsEtn enhances the degradation of Far1, thereby reducing the synthesis of PlsEtn. Far1 is a rate-limiting enzyme for plasmalogen synthesis. FAR1 deficiency is characterized by low levels of plasmalogens while FAR1 dysregulation is associated with elevated levels of plasmalogens. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24108123","rdfs:label":"Honsho_FA"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1}],"evidenceStrength":"Moderate","sequence":10869,"specifiedBy":"GeneValidityCriteria11","strengthScore":10.2,"subject":{"id":"https://genegraph.clinicalgenome.org/r/mPxWWyFHOmI","type":"GeneValidityProposition","disease":"obo:MONDO_0100230","gene":"hgnc:26222","modeOfInheritance":"obo:HP_0000006"},"version":"2.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_1068b8e8-36a1-4110-9ab4-45f9d4ece894-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}